Macquarie raised the firm’s price target on BeiGene (ONC) to $313 from $259 and keeps an Outperform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene price target raised to $348 from $345 at Guggenheim
- BeiGene price target raised to $348 from $288 at Citizens JMP
- BeiGene’s Strong Financial Performance and Strategic Positioning Earns Buy Rating
- BeiGene Faces Potential Tax Risks Amid Corporate Restructuring: Stakeholders Urged to Review SEC Filings
- BeiGene Reports Strong 2024 Financial Growth and Strategic Advancements